

1642
RECEIVED
JUL 25 2003
TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re: Application of: Chang

Art Unit: 1642

Application No. 09/826,115

CERTIFICATE OF MAILING

Filed: April 4, 2001

For: NUCLEIC ACID VACCINES FOR
PREVENTION OF FLAVIVIRUS
INFECTION

Examiner: Jeffrey S. Parkin

Date: July 21, 2003

I hereby certify that this paper and the documents referred to as being attached or enclosed herewith are being deposited with the United States Postal Service on July 21, 2003, as First Class Mail in an envelope addressed to: COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450.

Tanya M. Harding, Ph.D.
Attorney for Applicant

TRANSMITTAL LETTER

COMMISSIONER FOR PATENTS
P.O. BOX 1450
ALEXANDRIA, VA 22313-1450

Enclosed for filing in the application referenced above are the following:

- ☒ Supplemental Information Disclosure Statement
- ☒ Form 1449 and copies of the nine references cited thereon
- ☒ Status Letter
- ☒ The Director is hereby authorized to charge any additional fees that may be required, or credit over-payment, to Deposit Account No. 02-4550. A copy of this sheet is enclosed.
- ☒ Please return the enclosed postcard to confirm that the items listed above have been received.

Respectfully submitted,
KLARQUIST SPARKMAN, LLP

By

Tanya M. Harding, Ph.D.
Registration No. 42,630

One World Trade Center, Suite 1600
121 S.W. Salmon Street
Portland, Oregon 97204
Telephone: (503) 226-7391
Facsimile: (503) 228-9446
cc: Docketing



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Inventor application of: Chang
Application No. 09/826,115

Filed: April 4, 2001

For: NUCLEIC ACID VACCINES FOR
PREVENTION OF FLAVIVIRUS INFECTION

Examiner: Jeffrey S. Parkin

Date: July 21, 2003

Art Unit: 1642

CERTIFICATE OF MAILING

I hereby certify that this paper and the documents referred to as being attached or enclosed herewith are being deposited with the United States Postal Service on July 21, 2003 as First Class Mail in an envelope addressed to: COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450.

Tanya M. Harding, Ph.D.
Attorney for Applicant

RECEIVED
JUL 25 2003
TECH CENTER 1600/2900

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 C.F.R. § 1.97(b)(3)

COMMISSIONER FOR PATENTS
P.O. BOX 1450
ALEXANDRIA, VA 22313-1450

Listed on the accompanying form PTO-1449 and enclosed herewith are several English-language documents. Applicant respectfully requests that these documents be listed as references cited on the issued patent.

Applicant filed this Information Disclosure Statement ("IDS") before the mailing date of a first Office action on the merits. As a result, no fee should be required to file the IDS. However, if the Patent Office determines that a fee is required for Applicant to file this IDS, please see the attached Transmittal Letter for Deposit Account authority.

The filing of this IDS shall not be construed to be an admission that the information cited in the statement is, or is considered to be, prior art or otherwise material to patentability as defined in Rule 56.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

By

Tanya M. Harding, Ph.D.
Registration No. 42,630

One World Trade Center, Suite 1600
121 S.W. Salmon Street
Portland, Oregon 97204
Telephone: (503) 226-7391
Facsimile: (503) 228-9446



RECEIVED
JUL 25 2003
TECH CENTER 1600/2900

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Attorney Docket Number	6395-64908
Application Number	09/826,115
Filing Date	April 4, 2001
First Named Inventor	Chang
Art Unit	1642
Examiner Name	Jeffrey S. Parkin

FOREIGN PATENT DOCUMENTS

Examiner's Initials*	Cite No. (optional)	Number	Date	Country
		WO 98/37911	Sept. 3, 1998	WIPO
		WO 99/06068	Feb. 11, 1999	WIPO

OTHER DOCUMENTS

Examiner's Initials*	Cite No. (optional)	
		Colombage <i>et al.</i> , "DNA-Based and Alphavirus-Vectored Immunisation with PrM and E Proteins Elicits Long-Lived and Protective Immunity against the Flavivirus, Murray Valley Encephalitis Virus," <i>Virology</i> 250:151-163, 1998
		Konishi <i>et al.</i> , "The Anamnestic Neutralizing Antibody Response Is Critical for Protection of Mice from Challenge following Vaccination with a Plasmid Encoding the Japanese Encephalitis Virus Premembrane and Envelope Genes," <i>J. Virology</i> 73(7):5527-5534, July 1999
		Konishi <i>et al.</i> , "A DNA vaccine expressing dengue type 2 virus premembrane and envelope genes induces neutralizing antibody and memory B cells in mice," <i>Vaccine</i> 18:1133-1139, 2000
		Porter <i>et al.</i> , "Protective efficacy of a dengue 2 DNA vaccine in mice and the effect of CpG immuno-stimulatory motifs on antibody responses," <i>Arch. Virol.</i> 143:997-1003, 1998
		Raviprakash <i>et al.</i> , "Immunogenicity of dengue virus type 1 DNA vaccines expressing truncated and full length envelope protein," <i>Vaccine</i> 18:2426-2434, 2000
		Schimaljohn <i>et al.</i> , "Naked DNA Vaccines Expressing the prM and E Genes of Russian Spring Summer Encephalitis Virus and Central European Encephalitis Virus Protect Mice from Homologous and Heterologous Challenge," <i>J. Virology</i> 71(12):9563-9569, December 1997
		Wang <i>et al.</i> , "Immunization of Mice Against West Nile Virus with Recombinant Envelope Protein," <i>J. Immunol.</i> 167:5273-5277, 2001

EXAMINER
SIGNATURE:

DATE
CONSIDERED:

* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.